A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy.

Trial Profile

A Multicentre, Double-Blind, Double-Dummy, Two-Phase Crossover Study of Nasalfent (Fentanyl Citrate Nasal Spray) Compared to Immediate Release Morphine Sulphate Tablets in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2012

At a glance

  • Drugs Fentanyl; Morphine
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2012 Primary endpoint identified as (Assessment scale scores) as reported by European Clinical Trials Database record.
    • 21 Jun 2012 Planned number of patients changed from 80 to 200 as reported by European Clinical Trials Database record.
    • 21 Jun 2012 Inclusion and exclusion criteria amended as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top